- Home
- LIDR vs NXTC Comparison
LIDR vs NXTC Comparison
Compare LIDR & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- NXTC
- Stock Information
- Founded
- LIDR 2013
- NXTC 2015
- Country
- LIDR United States
- NXTC United States
- Employees
- LIDR N/A
- NXTC N/A
- Industry
- LIDR Auto Parts:O.E.M.
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- NXTC Health Care
- Exchange
- LIDR Nasdaq
- NXTC Nasdaq
- Market Cap
- LIDR 14.8M
- NXTC 13.9M
- IPO Year
- LIDR N/A
- NXTC 2019
- Fundamental
- Price
- LIDR $0.92
- NXTC $0.48
- Analyst Decision
- LIDR Hold
- NXTC Strong Buy
- Analyst Count
- LIDR 1
- NXTC 2
- Target Price
- LIDR N/A
- NXTC $3.50
- AVG Volume (30 Days)
- LIDR 577.6K
- NXTC 340.6K
- Earning Date
- LIDR 08-04-2025
- NXTC 07-31-2025
- Dividend Yield
- LIDR N/A
- NXTC N/A
- EPS Growth
- LIDR N/A
- NXTC N/A
- EPS
- LIDR N/A
- NXTC N/A
- Revenue
- LIDR $246,000.00
- NXTC N/A
- Revenue This Year
- LIDR $2,677.23
- NXTC N/A
- Revenue Next Year
- LIDR $409.09
- NXTC N/A
- P/E Ratio
- LIDR N/A
- NXTC N/A
- Revenue Growth
- LIDR N/A
- NXTC N/A
- 52 Week Low
- LIDR $0.49
- NXTC $0.22
- 52 Week High
- LIDR $4.30
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- LIDR 65.47
- NXTC 44.82
- Support Level
- LIDR $0.71
- NXTC $0.45
- Resistance Level
- LIDR $0.88
- NXTC $0.51
- Average True Range (ATR)
- LIDR 0.09
- NXTC 0.07
- MACD
- LIDR 0.00
- NXTC -0.01
- Stochastic Oscillator
- LIDR 89.21
- NXTC 3.24
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.